| Code | CSB-RA023606MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to DS-7011, targeting Toll-like receptor 7 (TLR7), a crucial pattern recognition receptor in the innate immune system. TLR7 is primarily expressed in plasmacytoid dendritic cells and B cells, where it recognizes single-stranded RNA from viruses and self-nucleic acids. Upon activation, TLR7 triggers signaling cascades through MyD88, leading to the production of type I interferons and pro-inflammatory cytokines. Dysregulated TLR7 signaling has been implicated in autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, and psoriasis, while also playing important roles in antiviral immunity and cancer immunotherapy responses.
DS-7011 represents a therapeutic antibody designed to modulate TLR7 activity and has been investigated for its potential in treating autoimmune conditions. This biosimilar antibody provides researchers with a valuable tool for investigating TLR7-mediated immune responses, studying the receptor's role in inflammatory disease pathogenesis, and exploring therapeutic interventions targeting innate immune pathways in preclinical models.
There are currently no reviews for this product.